et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med.
1996;334677- 681Link to Article
et al. for the Tasman Study Group, Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med.
1996;334682- 687Link to Article
et al. Antithrombotic therapy for venous thromboembolic disease. Chest.
176S- 193SLink to Article
HR Long-term treatment of venous thromboembolic disease. Thromb Haemost. 1999;82892- 898
van den Belt
et al. Recurrence of venous thromboembolism in patients with familial thrombophilia. Arch Intern Med.
1997;1572227- 2232Link to Article
J Duration of anticoagulant therapy after first episode of venous thrombosis in patients with inherited thrombophilia. Arch Intern Med.
1997;1572174- 2177Link to Article
MH Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism [Cochrane review]. Cochrane Database Syst Rev. 2000;CD001367
PA A prospective controlled study of the efficacy of short-term anticoagulation therapy in patients with deep vein thrombosis of the lower extremity. J Vasc Surg.
1998;28630- 637Link to Article
E Low recurrence rate after deep calf-vein thrombosis with 6 weeks of oral anticoagulation. J Intern Med.
1998;24479- 82Link to Article
Tfor the East Anglian Thrombophilia Study Group, Risk of recurrent venous thromboembolism in patients with the factor V Leiden (FVR506Q) mutation. Br J Haematol.
1998;100764- 768Link to Article
et al. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden. Thromb Haemost. 1997;77624- 628
J Assessment of outpatient treatment of deep-vein thrombosis with low-molecular-weight heparin. Arch Intern Med.
1998;1582001- 2003Link to Article
et al. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thromb Haemost. 1999;8126- 31
et al. Secondary prevention of venous thromboembolism. Haemostasis. 1998;28236- 243
Research Committee of the British Thoracic Society, Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Lancet. 1992;340873- 876
SB The efficacy and safety of oral anticoagulation in patients with cancer. Thromb Haemost. 1995;741055- 1058
SE Complications of anticoagulation for pulmonary embolism in low risk trauma patients. Chest.
1993;104718- 720Link to Article
et al. Effectiveness and safety of bolus administration of alteplase in massive pulmonary embolism. Am J Cardiol.
1992;701477- 1480Link to Article
et al. Clinical manifestations and management of inherited thrombophilia: retrospective analysis and follow-up after diagnosis of 238 patients with congenital deficiency of antithrombin III, protein C, protein S. Thromb Haemost. 1994;72352- 358
MH Efficacy and safety of early versus late initiation of warfarin during heparin therapy in acute thromboembolism. Am Heart J.
1992;123729- 732Link to Article
et al. Anticoagulant therapy in deep venous thrombosis. Thromb Res.
1994;73215- 226Link to Article
PM Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med.
1992;117303- 308Link to Article
DA Thromboembolic complications in patients with advanced cancer. Ann Vasc Surg.
1991;5186- 189Link to Article
C Early and late follow-up of pulmonary embolism. Respiration.
1993;6015- 20Link to Article
Jr Physician practices in the management of venous thromboembolism. J Vasc Surg.
1992;16707- 714Link to Article
Bfor the Duration of Anticoagulation (DURAC) Trial Study Group, The significance of hypofibrinolysis for the risk of recurrence of venous thromboembolism. Thromb Haemost. 1996;75607- 611
et al. for the Duration of Anticoagulation Trial Study Group, The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med.
1997;336393- 398Link to Article
et al. Factor V Leiden mutation as a risk factor for recurrent pregnancy loss. Ann Intern Med.
((12, pt 1))
1000- 1003Link to Article
A Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet.
1986;21293- 1296Link to Article
The Columbus Investigators, Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med.
1997;337657- 662Link to Article
RK Complications and failure of anticoagulation therapy in the treatment of venous thromboembolism in patients with disseminated malignancy. Aust N Z J Med.
1992;22119- 122Link to Article
JA An analysis of current pulmonary embolism therapy. Int Angiol. 1992;1157- 63
Jr The risk and efficacy of anticoagulant therapy in the treatment of thromboembolic complications in patients with primary malignant brain tumors. Neurosurgery.
1990;2774- 77Link to Article
J Safety and efficacy of long-term oral anticoagulation in cancer patients. Cancer.
1987;59983- 985Link to Article
A Recurrent pulmonary embolism: a prospective study. Chest.
1989;95976- 979Link to Article
H Recurrent venous thromboembolism after deep vein thrombosis. Arch Intern Med.
2000;160769- 774Link to Article
KL Duration of warfarin anticoagulant therapy and the probabilities of recurrent thromboembolism and hemorrhage. Am J Med.
1986;81255- 259Link to Article
RA Timing of oral anticoagulation therapy in the treatment of angiographically proven acute pulmonary embolism. Arch Intern Med.
1987;1471469- 1473Link to Article
et al. Oral anticoagulation therapy in pediatric patients: a prospective study. Thromb Haemost. 1994;71265- 269
et al. Influence of long term oral anticoagulants upon prothrombin fragment 1 + 2, thrombin-antithrombin III complex and D-dimer levels in patients affected by proximal deep vein thrombosis. Thromb Haemost. 1993;69302- 305
et al. The occurrence of subsequent malignancy in patients presenting with deep vein thrombosis. Thromb Haemost. 1998;7919- 22
et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med.
1990;3221260- 1264Link to Article
S Antithrombin III in patients with acute deep vein thrombosis during heparin treatment (subcutaneous and intravenous) and during and after treatment with oral coumarins. Thromb Res.
1984;34333- 340Link to Article
E Duration of anticoagulant therapy in venous thrombo-embolism. Med J Aust. 1972;21104- 1107
H Clinical presentation and results of thrombolytic therapy in older patients with massive pulmonary embolism: a comparison with non-elderly patients. J Am Geriatr Soc. 1996;44189- 193
T A retrospective study on oral anticoagulant prophylaxis in 103 Italian patients with hereditary thrombophilia and thrombosis. as hoc Study Group. Ric Clin Lab. 1990;20245- 252
J Home treatment of deep vein thrombosis: a two-year experience of a single institution. Haematologica. 1998;83438- 441
WT Anticoagulation therapy for venous thromboembolism in patients with gynecologic malignancy. Am J Obstet Gynecol. 1983;147369- 375
B Free-floating thrombus and embolic risk in patients with angiographically confirmed proximal deep venous thrombosis: a prospective study. Arch Intern Med.
1997;157305- 308Link to Article
H Secondary prevention after deep venous thrombosis: low molecular weight heparin versus coumarin. Zentralbl Chir. 1999;12424- 26
et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med.
1979;301855- 858Link to Article
GM The safety and effectiveness of long-term warfarin therapy in an anticoagulation clinic. Pharmacotherapy. 1989;9214- 219
RD The efficacy of long-term oral anticoagulant therapy and its laboratory assessment. J Clin Pathol.
1975;28198- 201Link to Article
V Anticoagulation clinics and the monitoring of anticoagulant therapy. Int J Cardiol.
1988;18197- 206Link to Article
VV Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World J Surg.
1996;20521- 527Link to Article
et al. Cancer-related thromboembolic disease in patients with solid tumours: a retrospective analysis. Ann Oncol.
1997;8669- 673Link to Article
et al. Equal effectiveness of very-low-intensity anticoagulation and standard low-intensity anticoagulation: a pilot study. South Med J.
1995;881136- 1139Link to Article
JNfor the Fragmin-Study Group, Adjusted versus fixed doses of the low-molecular-weight heparin Fragmin in the treatment of deep vein thrombosis. Thromb Haemost. 1994;71698- 702
et al. Subcutaneous low-molecular-weight heparin Fragmin versus intravenous unfractionated heparin in the treatment of acute non massive pulmonary embolism: an open randomized pilot study. Thromb Haemost. 1995;741432- 1435
et al. Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis. Thromb Haemost. 1996;76195- 199
et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thromb Haemost. 1992;6814- 18
et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. Arch Intern Med.
1993;1531541- 1546Link to Article
C Frequency of pulmonary embolism in patients who have iliofemoral deep vein thrombosis and are treated with once- or twice-daily low-molecular-weight heparin. J Vasc Surg.
1996;24774- 782Link to Article
et al. A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis. J Intern Med.
1996;24085- 92Link to Article
D Two daily subcutaneous injections of Fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis (DVT). Thromb Haemost. 1990;64506- 510
D A comparison between low molecular weight heparin (KABI 2165) and standard heparin in the intravenous treatment of deep venous thrombosis. Thromb Haemost. 1985;54813- 817
JJ Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin): results of a double-blind randomized study. Circulation.
1989;80935- 940Link to Article
et al. for the THESEE Study Group, A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med.
1997;337663- 669Link to Article
A Causes and outcome of deep-vein thrombosis in otherwise-healthy patients under 50 years. QJM.
1997;90283- 287Link to Article
et al. Antiphospholipid antibodies and venous thromboembolism. Blood. 1995;863685- 3691
JW The clinical course of patients with suspected pulmonary embolism. Arch Intern Med.
1997;1572593- 2598Link to Article
et al. Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin: a comparison of patient self-injection with homecare injection. Arch Intern Med.
1998;1581809- 1812Link to Article
PS Length of hospital stay for treatment of deep venous thrombosis and the incidence of recurrent thromboembolism. Arch Intern Med.
1998;1581005- 1010Link to Article
S Recurrent venous thromboembolism in a Spanish population: incidence, risk factors, and management in a hospital setting. Thromb Res.
1999;96335- 341Link to Article
et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet.
1992;339441- 445Link to Article
et al. Use of an algorithm for administering subcutaneous heparin in the treatment of deep venous thrombosis. Ann Intern Med.
1998;129299- 302Link to Article
HKfor the Certoparin-Study Group, Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis. Int Angiol. 1998;17135- 145
et al. Early versus delayed introduction of oral vitamin K antagonists in combination with low-molecular-weight heparin in the treatment of deep vein thrombosis: a randomized clinical trial. Haemostasis. 1998;2870- 77
et al. Coexistence of factor V Leiden and factor II A20210 mutations and recurrent venous thromboembolism. Thromb Haemost. 1999;821583- 1587
B Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency: a cooperative, retrospective study. Arterioscler Thromb Vasc Biol.
1996;16742- 748Link to Article
et al. Late results in deep vein thrombosis of the lower extremity. Vasa. 1985;14264- 268
H Prevention of recurrence after deep vein thrombosis: oral anticoagulation or subcutaneous low molecular weight heparin? Vasomed. 1998;10133- 136
et al. A simple ultrasound approach for detection of recurrent proximal-vein thrombosis. Circulation.
((4, pt 1))
1730- 1735Link to Article
et al. A noninvasive strategy for the treatment of patients with suspected pulmonary embolism. Arch Intern Med.
1994;154289- 297Link to Article
J Treatment of pulmonary embolism in total hip replacement. Clin Orthop. 1977;124149- 154
CS Long-term outcomes of deep-vein thrombosis. Arch Intern Med.
1995;1551031- 1037Link to Article
JE Low-dose heparin therapy in the long-term management of venous thromboembolism. Am J Med.
1979;67553- 556Link to Article
et al. for the American-Canadian Thrombosis Study Group, Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. Arch Intern Med.
2000;160229- 236Link to Article
et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med.
1996;1251- 7Link to Article
Sfor the Duration of Anticoagulation (DURAC) Trial Study Group, Quality of oral anticoagulant control and treatment in Sweden. J Intern Med.
1994;236143- 152Link to Article
Sfor the Duration of Anticoagulation (DURAC) Trial Study Group, The effect of the duration of anticoagulation and other risk factors on the recurrence of venous thromboembolisms. Wien Med Wochenschr. 1999;14966- 69
R Extended anticoagulation for a first episode of idiopathic venous thromboembolism. J Fam Pract. 1999;48579- 580
et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med.
1992;3271128- 1133Link to Article
D A 6-month venographic follow-up in 164 patients with acute deep vein thrombosis. Thromb Haemost. 1997;78803- 807
C Long-term clinical follow-up in 265 patients with deep venous thrombosis initially treated with either unfractionated heparin or dalteparin: a retrospective analysis. Thromb Haemost. 1999;821222- 1226
et al. The clinical course of deep-vein thrombosis: prospective long-term follow-up of 528 symptomatic patients. Haematologica. 1997;82423- 428
Sfor the DURAC Trial Study Group, The risk of ipsilateral versus contralateral recurrent deep vein thrombosis in the leg. J Intern Med.
2000;247601- 606Link to Article
et al. Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism. Thromb Haemost. 1998;80566- 569
et al. The risk of early recurrent venous thromboembolism after oral anticoagulant therapy in patients with the G20210A transition in the prothrombin gene. Thromb Haemost. 1999;8114- 17
A Prospective 12-year follow-up study of clinical and hemodynamic sequelae after deep vein thrombosis in low-risk patients (Zurich study). Circulation.
1996;9374- 79Link to Article
M Impaired fibrinolytic capacity predisposes for recurrence of venous thrombosis. Thromb Haemost. 1984;52127- 130
et al. A comparison of 3 and 6 weeks' anticoagulation in the treatment of venous thromboembolism. Clin Lab Haematol. 1987;917- 21
JH Rebound after cessation of oral anticoagulant therapy: the biochemical evidence. Br J Haematol.
1996;92479- 485Link to Article
R Management of a second episode of DVT or PE. J Fam Pract. 1997;44444- 445
GR The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med.
1995;332993- 997Link to Article
et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med.
1999;340901- 907Link to Article
JW Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med.
1992;3271485- 1489Link to Article
et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thromb Haemost. 1994;72191- 197
A The duration of oral anticoagulation after deep vein thrombosis: a randomized study. Acta Med Scand.
1985;217547- 552Link to Article
et al. for the Duration of Anticoagulation Trial Study Group, A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med.
1995;3321661- 1665Link to Article
U Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet.
1985;2515- 518Link to Article
et al. One-month versus six-month therapy with oral anticoagulants after symptomatic deep vein thrombosis. Acta Med Scand.
1985;218279- 284Link to Article
G Withdrawal of warfarin after deep vein thrombosis: effects of a low fixed dose on rebound thrombin generation. Blood Coagul Fibrinolysis.
1999;10291- 295Link to Article
et al. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med.
1982;306189- 194Link to Article
et al. Evolution of blood coagulation and fibrinolysis parameters after abrupt versus gradual withdrawal of acenocoumarol in patients with venous thromboembolism: a double-blind randomized study. Br J Haematol.
1997;96174- 178Link to Article
et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med.
1982;3071676- 1681Link to Article
D Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost. 1994;72186- 190
et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med.
1994;15449- 56Link to Article
et al. Venographic comparison of subcutaneous low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis. J Vasc Surg.
1999;30283- 292Link to Article
et al. for the Warfarin Optimal Duration Italian Trial Investigators, Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. N Engl J Med.
2001;345165- 169Link to Article
et al. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation.
2001;1032453- 2460Link to Article
et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost. 1995;74606- 611
et al. The risk of recurrent venous thromboembolism in patients with an Arg50→Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med.
1997;336399- 403Link to Article
L The international normalized ratio: a guide to understanding and correcting its problems. Arch Intern Med.
1994;154282- 288Link to Article
et al. One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial: a randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction. J Am Coll Cardiol.
1995;261643- 1650Link to Article
L Low-molecular-weight heparin as a bridge to timely revascularization in unstable coronary artery disease: an update of the Fragmin During Instability in Coronary Artery Disease II Trial. Haemostasis. 2000;30
et al. Activation of blood coagulation after abrupt or stepwise withdrawal of oral anticoagulants: a prospective study. Thromb Haemost. 1994;72222- 226
DG Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA.
1995;273408- 412Link to Article
JS Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA.
1998;279458- 462Link to Article
et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet.
1996;348423- 428Link to Article